A Phase 4 interventional study of Basiliximab and Enteric Coated Mycophenolic Acid (MPA) in Renal Transplantation, sponsored by Novartis Pharmaceuticals. Terminated at 9 sites in Germany. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2014-06-06.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study wants to address whether a calcineurin-inhibitor (CNI)-free regimen six weeks after transplantation for Eurotransplant Senior Program (ESP) patients is as safe and well tolerated as standard treatment but optimizing immunosuppressive therapy with benefits in renal function, new-onset diabetes mellitus, cardiovascular risk, cancer and allograft nephropathy.
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group continued with a CNI-based regimen of MPA and CsA.
Drug: Basiliximab · Drug: Enteric Coated Mycophenolic Acid (MPA) · Drug: Cyclosporin A (CsA) · Drug: Corticosteroids
During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group made a stepwise switch to a CNI-free regimen of everolimus and MPA.
Drug: Basiliximab · Drug: Enteric Coated Mycophenolic Acid (MPA) · Drug: RAD001 · Drug: Cyclosporin A (CsA) · Drug: Corticosteroids
On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
Also known as: Simulect
A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
Also known as: Myfortic
Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
Also known as: RAD001, Certcian
Dosage was based according to blood level
Also known as: Sandimmun Optoral
Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
Renal Function by Glomerular Filtration Rate (GFR) Via Cockcroft-Gault Method
The study was terminated prematurely and not powered for efficacy.
Time frame: Month 6
Renal Function by GFR Via Modification of Diet in Renal Diseases (MDRD) and Nankivell Method
The study was terminated prematurely and not powered for efficacy.
Time frame: Month 6
Renal Function by Serum Creatinine
The study was terminated prematurely and not powered for efficacy.
Time frame: Months 6, 12, 24, 36, 48 and 60
Biopsy Proven Acute Rejection (BPAR), Graft Loss and Death
The study was terminated prematurely and not powered for efficacy.
Time frame: Months 6, 12, 24, 36, 48 and 60
Occurrence of Treatment Failures
The study was terminated prematurely and not powered for efficacy.
Time frame: Month 6
Evolution of Renal Function (Creatinine Slope)
The study was terminated prematurely and not powered for efficacy.
Time frame: Week 7, Month 6
CD25 Saturation on Lymphocytes
Time frame: Month 6
Number of Participants Who Experienced Adverse Events, Serious Adverse Events and Death
Participants with adverse events (serious plus non-serious), serious adverse events and death were reported.
Time frame: Months 6, 12, 24, 36, 48 and 60
Renal Function by GFR Over Time
Time frame: Months 12, 24, 36, 48 and 60
Renal Function by Proteinuria
Time frame: Months12, 24, 36, 48 and 60
The study consisted of a main period and a 54 month observation follow-up period. The main period included a pre-randomized treatment phase (6 weeks) and a randomized treatment phase (18 weeks). All randomized participants, who participated in the main period, were eligible for the follow-up period.
| Milestone | Control Group | Everolimus Group | Pre-randomized Group |
|---|---|---|---|
| Started | 0 | 0 | 207 |
| Enrolled safety set | 0 | 0 | 203 |
| Completed | 0 | 0 | 77 |
| Not completed | 0 | 0 | 130 |
| Withdrew: Not specified (data missing) | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Abnormal test procedure result | 0 | 0 | 2 |
| Withdrew: Administrative problems | 0 | 0 | 6 |
| Withdrew: Graft loss | 0 | 0 | 7 |
| Withdrew: Withdrawal by subject | 0 | 0 | 12 |
| Withdrew: Lack of efficacy | 0 | 0 | 20 |
| Withdrew: Adverse event | 0 | 0 | 36 |
| Withdrew: Abnormal laboratory value | 0 | 0 | 44 |
| Milestone | Control Group | Everolimus Group | Pre-randomized Group |
|---|---|---|---|
| Started | 24 | 53 | 0 |
| Full analysis set | 24 | 51 | 0 |
| Randomized safety set | 24 | 51 | 0 |
| Completed | 23 | 26 | 0 |
| Not completed | 1 | 27 | 0 |
| Withdrew: Abnormal laboratory value | 0 | 2 | 0 |
| Withdrew: Lack of efficacy | 1 | 10 | 0 |
| Withdrew: Adverse event | 0 | 15 | 0 |
| Milestone | Control Group | Everolimus Group | Pre-randomized Group |
|---|---|---|---|
| Started | 20 | 32 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 20 | 32 | 0 |
| Withdrew: Follow-up period was terminated. | 20 | 32 | 0 |
The study was terminated prematurely and not powered for efficacy.
No measurements were reported for this outcome.
The study was terminated prematurely and not powered for efficacy.
No measurements were reported for this outcome.
The study was terminated prematurely and not powered for efficacy.
No measurements were reported for this outcome.
The study was terminated prematurely and not powered for efficacy.
No measurements were reported for this outcome.
The study was terminated prematurely and not powered for efficacy.
No measurements were reported for this outcome.
The study was terminated prematurely and not powered for efficacy.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Participants with adverse events (serious plus non-serious), serious adverse events and death were reported.
| Participants | Control Group | Everolimus Group |
|---|---|---|
| Adverse events (serious and non-serious) | 21 | 50 |
| Serious adverse events | 11 | 28 |
| Deaths | 0 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control Goup | — | 11/24 (45.8%) | 15/24 (62.5%) |
| Everolimus Group | — | 28/51 (54.9%) | 50/51 (98%) |
| Event | Control Goup | Everolimus Group |
|---|---|---|
| BLOOD CREATININE INCREASEDInvestigations | 4/24 | 5/51 |
| URINARY TRACT INFECTIONInfections and infestations | 3/24 | 5/51 |
| INFECTIONInfections and infestations | 2/24 | 1/51 |
| PNEUMONIAInfections and infestations | 2/24 | 4/51 |
| LEUKOPENIABlood and lymphatic system disorders | 0/24 | 3/51 |
| ANAEMIABlood and lymphatic system disorders | 1/24 | 2/51 |
| MITRAL VALVE INCOMPETENCECardiac disorders | 1/24 | 0/51 |
| TRANSPLANT REJECTIONImmune system disorders | 1/24 | 0/51 |
| HEPATIC CYST INFECTIONInfections and infestations | 1/24 | 0/51 |
| ANURIARenal and urinary disorders | 1/24 | 0/51 |
| Event | Control Goup | Everolimus Group |
|---|---|---|
| URINARY TRACT INFECTIONInfections and infestations | 6/24 | 22/51 |
| LEUKOPENIABlood and lymphatic system disorders | 4/24 | 20/51 |
| OEDEMA PERIPHERALGeneral disorders | 7/24 | 13/51 |
| HYPOKALAEMIAMetabolism and nutrition disorders | 0/24 | 12/51 |
| DIARRHOEAGastrointestinal disorders | 0/24 | 10/51 |
| APHTHOUS STOMATITISGastrointestinal disorders | 0/24 | 9/51 |
| PYREXIAGeneral disorders | 4/24 | 5/51 |
| PROTEINURIARenal and urinary disorders | 0/24 | 8/51 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 3/24 | 3/51 |
| HYPERTENSIONVascular disorders | 3/24 | 6/51 |
| Age, Continuous(Years) | Control Group | Everolimus Group | Total |
|---|---|---|---|
| Mean | 69.3 ± 3.1 | 68.4 ± 3.3 | 68.7 ± 3.3 |
| Sex: Female, Male(Participants) | Control Group | Everolimus Group | Total |
|---|---|---|---|
| Female | 8 | 26 | 34 |
| Male | 16 | 25 | 41 |
The record gives a start of Jul 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus